Welcome to our dedicated page for Pharvaris N.V. SEC filings (Ticker: PHVS), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Interpreting Pharvaris NV filings can be daunting—one press release about a trial pause can hide inside a 300-page 10-K, and pivotal Phase 3 updates often arrive as dense 8-Ks. If you have ever asked, “How do I find Pharvaris insider trading Form 4 transactions before the next data read-out?” this page is built for you.
Stock Titan’s AI reads each document the moment it hits EDGAR and surfaces what busy biotech investors need to see—cash runway tables, FDA feedback, and management stock moves. Whether you are searching for “Pharvaris quarterly earnings report 10-Q filing” to track R&D spend, or need “Pharvaris Form 4 insider transactions real-time” alerts to gauge executive conviction, every filing type is here and explained simply.
- 10-K & 10-Q: Understand trial timelines, dilution risk, and liquidity with our plain-English summaries—perfect for anyone Googling “Pharvaris annual report 10-K simplified.”
- 8-K material events explained: Rapid AI digests of clinical holds, fast-track designations, or equity offerings delivered as they post.
- Form 4 insider trading: Track “Pharvaris executive stock transactions Form 4” in real time and spot buying or selling patterns ahead of catalysts.
- Proxy statement executive compensation: Quickly see how milestone bonuses align with deucrictibant progress.
Stop scrolling through PDF after PDF. Stock Titan answers practical questions—“What does Pharvaris disclose about deucrictibant safety?” “How to read Pharvaris SEC documents with AI?”—so you can focus on decision-making, not deciphering biotech jargon.
Pharvaris (NASDAQ: PHVS) filed a Form 6-K reporting the voting outcomes of its Annual General Meeting held on 27 June 2025.
Shareholders approved every agenda item: (1) adoption of the Dutch statutory annual accounts for the fiscal year ended 31 December 2024; (2) appointment of PricewaterhouseCoopers Accountants N.V. as external independent auditor for fiscal 2025; (3) discharge of directors from liability for FY 2024; (4) extension of the Board’s authorization to repurchase shares and depository receipts; and (5) re-appointment of non-executive directors Dr. Meeker, Dr. Glassman, and Ms. Monges.
The filing contains no new financial results, strategic transactions, or material operational changes.
FAQ
What is the current stock price of Pharvaris N.V. (PHVS)?
What is the market cap of Pharvaris N.V. (PHVS)?
What is the primary focus of Pharvaris NV?
What is deucrictibant and how is it used?
Which clinical trials are currently underway for Pharvaris NV?
How does Pharvaris differentiate itself in the market?
Who are the intended patients for Pharvaris NV's therapies?
How does the company ensure the quality and safety of its clinical trials?
